The $8.5m acquisition of an immunohaematology business strengthens PGC’s product offering, broadens relationships, is well within balance sheet capacity, and maintains strategic impetus. Acquisitive and organic growth to date has been well managed and suggests upside risk to our forecasts. We maintain a positive view and buy call on a valuation that has been upgraded slightly to $1.15 (prior $1.12).
To access our review of Paragon Care please log in under the Client Area Log In at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.
+61 8 9224 6888
+852 3557 4888